Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Lysophosphatidic acid mediates skeletal muscle fibrosis in denervation via activation of YAP/TAZ
Meilyn Cruz-Soca, Adriana Córdova-Casanova, Jennifer Faundez-Contreras, Nicolás W. Martínez, Francesca Vaccaro-Rivera, Sebastián Bazaes-Astorga, Cristian Gutiérrez-Rojas, Felipe S. Gallardo, Daniela L. Rebolledo, Felipe A. Court, Jerold Chun, Carlos P. Vio, Soledad Matus, Juan Carlos Casar, Enrique Brandan
Meilyn Cruz-Soca, Adriana Córdova-Casanova, Jennifer Faundez-Contreras, Nicolás W. Martínez, Francesca Vaccaro-Rivera, Sebastián Bazaes-Astorga, Cristian Gutiérrez-Rojas, Felipe S. Gallardo, Daniela L. Rebolledo, Felipe A. Court, Jerold Chun, Carlos P. Vio, Soledad Matus, Juan Carlos Casar, Enrique Brandan
View: Text | PDF
Research Article Cell biology Muscle biology

Lysophosphatidic acid mediates skeletal muscle fibrosis in denervation via activation of YAP/TAZ

  • Text
  • PDF
Abstract

Lysophosphatidic acid (LPA) is a bioactive lipid that signals through G protein–coupled receptors (LPA1–6) and regulates multiple cellular processes, including fibrosis. Although LPA signaling has been implicated in fibrotic diseases in several organs, its role in skeletal muscle remains unclear. Here, we show that LPA/LPA1 signaling promotes fibrogenesis after sciatic nerve transection. Denervation induces differential expression of LPA signaling axis components and a transient early increase in intramuscular LPA levels. Pharmacological inhibition of LPA1/3 with Ki16425, or genetic deletion of LPA1, reduces extracellular matrix accumulation and expansion of fibro/adipogenic progenitors (FAPs) in denervated muscle. Although LPA blockade suppresses atrophy-related gene expression, it does not fully preserve myofiber size. Mechanistically, denervation increases YAP/TAZ expression, nuclear localization in FAPs, and transcriptional activity, effects that are attenuated by LPA axis inhibition. Furthermore, pharmacological inhibition of YAP/TAZ with verteporfin reduces fibrosis after denervation, supporting their role as critical downstream mediators. Finally, transient denervation activates the LPA axis, promotes muscle fibrosis, reduces axonal density in the sciatic nerve, and increases neuromuscular junction instability, effects reversed by Ki16425. Together, these findings identify the LPA/LPA1/YAP/TAZ pathway as a key driver of denervation-induced muscle fibrosis and a potential therapeutic target in neuromuscular disorders.

Authors

Meilyn Cruz-Soca, Adriana Córdova-Casanova, Jennifer Faundez-Contreras, Nicolás W. Martínez, Francesca Vaccaro-Rivera, Sebastián Bazaes-Astorga, Cristian Gutiérrez-Rojas, Felipe S. Gallardo, Daniela L. Rebolledo, Felipe A. Court, Jerold Chun, Carlos P. Vio, Soledad Matus, Juan Carlos Casar, Enrique Brandan

×

Figure 5

YAP and TAZ induction after denervation requires the LPA axis.

Options: View larger image (or click on image) Download as PowerPoint
YAP and TAZ induction after denervation requires the LPA axis.
(A) Weste...
(A) Western blot and quantification of YAP and TAZ in 6-month-old C57Bl/6J mice treated with vehicle (DMSO) or Ki16425 for 3 days before undergoing unilateral sciatic nerve denervation, with tissues collected 2 weeks after denervation (n = 3 per group). GAPDH was used as a loading control. (B) Relative mRNA levels of cellular communication network factor 1 (Ccn1), transgelin 2 (Tagln2), and ankyrin (Ankrd1) in GST from mice treated with DMSO or Ki16425, with tissues collected 2 weeks after denervation. (C) EGFP-positive nuclei and YAP/TAZ immunofluorescence in tissue cross-sections from the GST of 6-month-old PDGFRαH2BEGFP knock-in reporter mice treated with DMSO (n = 3) or Ki16425 (n = 3) for 3 days before undergoing unilateral sciatic nerve denervation, with tissues collected 4 days after denervation. The lower panel shows EGFP+ YAP/TAZ+ nuclei identified by Fiji-based overlap analysis (Binary Feature Extractor, ≥50% overlap threshold), representing the subset of FAP nuclei with nuclear YAP/TAZ localization. (D) Quantification of the percentage of FAP nuclei positive for YAP/TAZ. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, with 1-way ANOVA test. Values are shown as mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts